株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

嚢胞性線維症治療薬の世界市場予測・パイプライン分析

Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis - Global Forecast to 2024

発行 iGate Research Pvt Ltd 商品コード 563629
出版日 ページ情報 英文 121 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
嚢胞性線維症治療薬の世界市場予測・パイプライン分析 Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis - Global Forecast to 2024
出版日: 2017年10月09日 ページ情報: 英文 121 Pages
概要

当レポートでは、世界の嚢胞性線維症治療薬市場を調査し、薬理学クラス・地域別の市場規模の推移と予測、主要企業の分析、市場成長推進因子および市場課題の分析などをまとめています。

第1章 エグゼクティブサマリー

第2章 世界の嚢胞性線維症治療薬市場・予測

第3章 世界の嚢胞性線維症治療薬市場シェア・予測

  • 地域別
  • 薬理学クラス別

第4章 世界の嚢胞性線維症治療薬市場:主な上市製品の売上・予測

  • Orkambi (Lumacaftor/Ivacaftor) 売上・予測
  • Kalydeco (Ivacaftor) 売上・予測
  • Cayston (Inhaled Aztreonam) 売上・予測
  • Pulmozyme (Dornase Alfa) 売上・予測
  • TOBI/ TOBI Podhaler 売上
  • Creon 売上・予測
  • Zenpep 売上・予測
  • Ventolin 売上・予測
  • Bronchitol (Inhaled Mannitol) 売上・予測
  • ADEKplusTM
  • Ibuprofen

第5章 世界の嚢胞性線維症治療薬市場:薬理学クラス別の売上・予測

  • CFTR調整剤の売上・予測
  • 粘液溶解薬
  • 膵酵素補充製品の売上・予測
  • 抗体の売上・予測
  • その他治療薬の売上・予測

第6章 地域別:嚢胞性線維症治療薬市場

  • 米国
  • カナダ
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • オーストラリア
  • 日本
  • 中国
  • インド
  • 韓国

第7章 世界の嚢胞性線維症パイプライン製品分析:企業 & 開発段階別

第8章 嚢胞性線維症の企業プロファイル、認可済み & パイプライン製品の分析

  • Genentech, Inc. (A Member of the Roche Group)
  • Novartis
  • Gilead Sciences, Inc.
  • Vertex Pharmaceuticals Incorporated
  • AbbVie
  • GlaxoSmithKline
  • Johnson & Johnson
  • Allergan plc
  • Pharmaxis Ltd
  • Mylan N.V.

第9章 世界の嚢胞性線維症市場:産業動向・発展

  • 遺伝子検査
  • 技術進歩
  • CFTR調整剤:躍進
  • 戦略的協力の数が急増
  • 併用療法
  • ベンダーによる自己負担・援助プログラム
  • R&D活動の増加:市場成長促進因子

第10章 世界の嚢胞性線維症市場:市場成長推進因子

  • たくましいパイプライン
  • 嚢胞性線維症の有病率増加
  • 診断技術の改善
  • 医療のアンメットニーズ

第11章 世界の嚢胞性線維症市場:市場課題

図表リスト

目次

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR. The increasing prevalence of cystic fibrosis, rising awareness about cystic fibrosis therapy, strong pipeline candidates, technological advancement and high rate of R&D initiatives are some of the major factors that are driving cystic fibrosis therapeutics market. However, high cost involved in treatment, increase in complexity of disease are restraining the cystic fibrosis therapeutics market.

Key Highlights of the Report

  • United States dominates the global market for cystic fibrosis therapeutics.
  • The EU5 countries together accounted for over 20% share of the global cystic fibrosis market in 2016.
  • In Asian region, the prevalence of Cystic Fibrosis is observed to be very low in countries like China, India and Japan.
  • On the basis of pharmacological class, the CFTR modulator captures highest share of the total CF therapeutics market in 2016.
  • In 2016, mucolyctics agents accounted for around xx% of the global cystic fibrosis therapeutics market.
  • Cystic Fibrosis patients who have reduced the levels of digestive enzymes due to improper functioning of pancreas, are treated by PERT to replace these enzymes.
  • In 20XX, TOBI Podhaler generated sales worth US$ 300 Million.
  • Italy has followed Ireland and other EU countries such as Germany, Austria, Denmark and Luxembourg in approving Orkambi for patients with CF.
  • It's estimated that 1 in every 2,500 babies born in the UK has cystic fibrosis.
  • The revenues for Creon increased 22 percent in 2015, driven primarily by continued market growth.
  • Zenpep sales surpassed US$ 200 Million mark in 2016.
  • Some of the drugs that are under clinical studies are Tezacaftor (VX-661) + ivacaftor, VX-445 + tezacaftor + ivacaftor, VX-659 + tezacaftor + ivacaftor, PTI-428, AZD5634, QR-010 and POL6014 among many others.

iGATE RESEARCH report titled "Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis - Global Forecast to 2024" provides a comprehensive assessment of the Cystic Fibrosis Therapeutics Market.

This 121 Page report with 53 Figures and 6 Tables has been studied from 8 View Points:

  • 1. Global Cystic Fibrosis Therapeutics Market & Forecast (2014 - 2024)
  • 2. Global Cystic Fibrosis Therapeutics Market - Major Marketed Products Sales & Forecast (2012 - 2024)
  • 3. Global Cystic Fibrosis Therapeutics Market - Pharmacological Class Sales & Forecast (2015 - 2021)
  • 4. By Geography - Cystic Fibrosis Therapeutics Market (2014 - 2024)
  • 5. Global Cystic Fibrosis Pipeline Product Analysis - By Company & Phase of Development
  • 6. Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis
  • 7. Global Cystic Fibrosis Market - Industry Trends & Developments
  • 8. Global Cystic Fibrosis Market - Growth Drivers & Challenges

Global Cystic Fibrosis Therapeutics Market - Major Marketed Products Covered

  • 1. Orkambi (Lumacaftor/Ivacaftor)
  • 2. Kalydeco (Ivacaftor)
  • 3. Cayston (Inhaled Aztreonam)
  • 4. Pulmozyme (Dornase Alfa)
  • 5. TOBI/ TOBI Podhaler
  • 6. Creon
  • 7. Zenpep
  • 8. Ventolin
  • 9. Bronchitol (Inhaled Mannitol)
  • 10. ADEKplusTM
  • 11. Ibuprofen

Global Cystic Fibrosis Therapeutics Market - Pharmacological Class

  • CFTR Modulators
  • Mucolytic Agents
  • Pancreatic Enzyme Replacement Products
  • Antibiotics
  • Other Therapies

Cystic Fibrosis Therapeutics Market - Geographical Analysis

  • 1. United States
  • 2. Canada
  • 3. France
  • 4. Germany
  • 5. Italy
  • 6. Spain
  • 7. United Kingdom
  • 8. Australia
  • 9. Japan
  • 10. China
  • 11. India
  • 12. South Korea

Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis

  • 1. Genentech, Inc. (A Member of the Roche Group)
  • 2. Novartis
  • 3. Gilead Sciences, Inc.
  • 4. Vertex Pharmaceuticals Incorporated
  • 5. AbbVie
  • 6. GlaxoSmithKline
  • 7. Johnson & Johnson
  • 8. Allergan plc
  • 9. Pharmaxis Ltd
  • 10. Mylan N.V

Data Sources

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Table of Contents

1. Executive Summary

2. Global Cystic Fibrosis Therapeutics Market & Forecast (2014 - 2024)

3. Global Cystic Fibrosis Therapeutics Market Share & Forecast

  • 3.1 By Geography - Cystic Fibrosis Therapeutics Market Share & Forecast (2014 - 2024)
  • 3.2 By Pharmacological Class - Cystic Fibrosis Therapeutics Market Share & Forecast (2015 - 2021)

4. Global Cystic Fibrosis Therapeutics Market - Major Marketed Products Sales & Forecast

  • 4.1 Orkambi (Lumacaftor/Ivacaftor) Sales & Forecast (2015 - 2021)
  • 4.2 Kalydeco (Ivacaftor) Sales & Forecast (2012 - 2021)
  • 4.3 Cayston (Inhaled Aztreonam) Sales & Forecast (2010 - 2021)
  • 4.4 Pulmozyme (Dornase Alfa) Sales & Forecast (2012 - 2021)
  • 4.5 TOBI/ TOBI Podhaler Sales (2012 - 2016)
  • 4.6 Creon Sales & Forecast (2011 - 2021)
  • 4.7 Zenpep Sales & Forecast (2014 - 2021)
  • 4.8 Ventolin Sales & Forecast (2012 - 2021)
  • 4.9 Bronchitol (Inhaled Mannitol) Sales & Forecast (2013 - 2021)
  • 4.10 ADEKplusTM
  • 4.11 Ibuprofen

5. Global Cystic Fibrosis Therapeutics Market - Pharmacological Class Sales & Forecast (2015 - 2021)

  • 5.1 CFTR Modulators Sales & Forecast
  • 5.2 Mucolytic Agents Sales & Forecast
  • 5.3 Pancreatic Enzyme Replacement Products Sales & Forecast
  • 5.4 Antibiotics Sales & Forecast
  • 5.5 Other Therapies Sales & Forecast

6. By Geography - Cystic Fibrosis Therapeutics Market (2014 - 2024)

  • 6.1 United States Cystic Fibrosis Therapeutics Market & Forecast
  • 6.2 Canada Cystic Fibrosis Therapeutics Market & Forecast
  • 6.3 France Cystic Fibrosis Therapeutics Market & Forecast
  • 6.4 Germany Cystic Fibrosis Therapeutics Market & Forecast
  • 6.5 Italy Cystic Fibrosis Therapeutics Market & Forecast
  • 6.6 Spain Cystic Fibrosis Therapeutics Market & Forecast
  • 6.7 United Kingdom Cystic Fibrosis Therapeutics Market & Forecast
  • 6.8 Australia Cystic Fibrosis Therapeutics Market & Forecast
  • 6.9 Japan Cystic Fibrosis Therapeutics Market & Forecast
  • 6.10 China Cystic Fibrosis Therapeutics Market & Forecast
  • 6.11 India Cystic Fibrosis Therapeutics Market & Forecast
  • 6.12 South Korea Cystic Fibrosis Therapeutics Market & Forecast

7. Global Cystic Fibrosis Pipeline Product Analysis - By Company & Phase of Development

8. Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis

  • 8.1 Genentech, Inc. (A Member of the Roche Group)
  • 8.2 Novartis
  • 8.3 Gilead Sciences, Inc.
  • 8.4 Vertex Pharmaceuticals Incorporated
  • 8.5 AbbVie
  • 8.6 GlaxoSmithKline
  • 8.7 Johnson & Johnson
  • 8.8 Allergan plc
  • 8.9 Pharmaxis Ltd
  • 8.10 Mylan N.V.

9. Global Cystic Fibrosis Market - Industry Trends & Developments

  • 9.1 Genetic Testing
  • 9.2 Technological Advances
  • 9.3 CFTR Modulators - Gaining Momentum
  • 9.4 Upsurge in the Number of Strategic Collaborations
  • 9.5 Combination Therapy
  • 9.6 Co-pay and Assistance Programs by Vendors
  • 9.7 Increased R&D Activities: Drives Market Growth

10. Global Cystic Fibrosis Market - Growth Drivers

  • 10.1 Robust Pipeline
  • 10.2 Increasing Prevalence of Cystic Fibrosis
  • 10.3 Improvement in Diagnostic Technologies
  • 10.4 Unmet Medical Needs

11. Global Cystic Fibrosis Market - Challenges

List of Figures:

  • Figure 2-1: Global - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 2-2: Global - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 4-1: Global - Orkambi (Lumacaftor/Ivacaftor) Sales (Million US$), 2015 - 2016
  • Figure 4-2: Global - Forecast for Orkambi (Lumacaftor/Ivacaftor) Sales (Million US$), 2017 - 2021
  • Figure 4-3: Global - Kalydeco (Ivacaftor) Sales (Million US$), 2012 - 2016
  • Figure 4-4: Global - Forecast for Kalydeco (Ivacaftor) Sales (Million US$), 2017 - 2021
  • Figure 4-5: Global - Cayston (Inhaled Aztreonam) Sales (Million US$), 2010 - 2016
  • Figure 4-6: Global - Forecast for Cayston (Inhaled Aztreonam) Sales (Million US$), 2017 - 2021
  • Figure 4-7: Global - Pulmozyme (Dornase Alfa) Sales (Million US$), 2012 - 2016
  • Figure 4-8: Global - Forecast for Pulmozyme (Dornase Alfa) Sales (Million US$), 2017 - 2021
  • Figure 4-9: Global - TOBI/ TOBI Podhaler Sales (Million US$), 2012 - 2016
  • Figure 4-10: Global - Creon Sales (Million US$), 2011 - 2016
  • Figure 4-11: Global - Forecast for Creon Sales (Million US$), 2017 - 2021
  • Figure 4-12: Global - Zenpep Sales (Million US$), 2014 - 2016
  • Figure 4-13: Global - Forecast for Zenpep Sales (Million US$), 2017 - 2021
  • Figure 4-14: Global - Ventolin Sales (Million US$), 2012 - 2016
  • Figure 4-15: Global - Forecast for Ventolin Sales (Million US$), 2017 - 2021
  • Figure 4-16: Global - Bronchitol (Inhaled Mannitol) Sales (Million US$), 2013 - 2016
  • Figure 4-17: Global - Forecast for Bronchitol (Inhaled Mannitol) Sales (Million US$), 2017 - 2021
  • Figure 5-1: Global Cystic Fibrosis Therapeutics - CFTR Modulators Sales (Million US$), 2015 - 2016
  • Figure 5-2: Global Cystic Fibrosis Therapeutics - Forecast for CFTR Modulators Sales (Million US$), 2017 - 2021
  • Figure 5-3: Global Cystic Fibrosis Therapeutics - Mucolytic Agents Sales (Million US$), 2015 - 2016
  • Figure 5-4: Global Cystic Fibrosis Therapeutics - Forecast for Mucolytic Agents Sales (Million US$), 2017 - 2021
  • Figure 5-5: Global Cystic Fibrosis Therapeutics - Pancreatic Enzyme Replacement Products Sales (Million US$), 2015 - 2016
  • Figure 5-6: Global Cystic Fibrosis Therapeutics - Forecast for Pancreatic Enzyme Replacement Products Sales (Million US$), 2017 - 2021
  • Figure 5-7: Global Cystic Fibrosis Therapeutics - Antibiotics Sales (Million US$), 2015 - 2016
  • Figure 5-8: Global Cystic Fibrosis Therapeutics - Forecast for Antibiotics Sales (Million US$), 2017 - 2021
  • Figure 5-9: Global Cystic Fibrosis Therapeutics - Other Therapies Sales (Million US$), 2015 - 2016
  • Figure 5-10: Global Cystic Fibrosis Therapeutics - Forecast for Other Therapies Sales (Million US$), 2017 - 2021
  • Figure 6-1: United States - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-2: United States - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-3: Canada - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-4: Canada - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-5: France - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-6: France - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-7: Germany - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-8: Germany - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-9: Italy - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-10: Italy - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-11: Spain - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-12: Spain - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-13: United Kingdom - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-14: United Kingdom - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-15: Australia - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-16: Australia - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-17: Japan - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-18: Japan - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-19: China - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-20: China - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-21: India - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-22: India - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024
  • Figure 6-23: South Korea - Cystic Fibrosis Therapeutics Market (Million US$), 2014 - 2016
  • Figure 6-24: South Korea - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 - 2024

List of Tables:

  • Table 3-1: By Geography - Cystic Fibrosis Therapeutics Market Share (Percent), 2014 - 2016
  • Table 3-2: By Geography - Forecast for Cystic Fibrosis Therapeutics Market Share (Percent), 2017 - 2024
  • Table 3-3: By Pharmacological Class - Cystic Fibrosis Therapeutics Market Share (Percent), 2015 - 2016
  • Table 3-4: By Pharmacological Class - Forecast for Cystic Fibrosis Therapeutics Market Share (Percent), 2017 - 2021
  • Table 7-1: Global - Cystic Fibrosis Pipeline Product (Pre-Clinical, Phase 1, Phase 2, Phase 3), 2017
  • Table 10-1: Cystic Fibrosis - List of Pipeline Drugs (as of September 2017)
Back to Top